Improving CAR T-cell therapy for various cancers
Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors
This research aims to make CAR T-cell therapy work better for more types of cancer, including those that are hard to treat or come back after initial treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11163699 on NIH RePORTER |
What this research studies
CAR T-cell therapy has been a breakthrough for some blood cancers, but it doesn't always work for solid tumors or for patients whose cancer returns. This project is developing new ways to make CAR T-cells stronger and more effective against different cancer types. Researchers are working on methods to help CAR T-cells find and stick to cancer cells better, and to last longer in the body. They are also exploring how to target multiple cancer markers at once to prevent the cancer from escaping treatment. This work uses advanced techniques to understand and overcome resistance to CAR T-cell treatments.
Who could benefit from this research
Good fit: Patients with various solid and liquid tumors, including acute myeloid leukemia, glioblastoma, pancreatic cancer, and multiple myeloma, who may not respond to current CAR T-cell therapies, could potentially benefit from future applications of this research.
Not a fit: Patients whose cancer types are not targeted by CAR T-cell therapy or who are not suitable for cell-based therapies may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and lasting CAR T-cell treatments for a wider range of cancers, offering new hope to patients.
How similar studies have performed: CAR T-cell therapy has already shown remarkable success in treating certain B cell blood cancers, and this work builds upon that foundation to expand its effectiveness.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Maus, Marcela Valderrama — Massachusetts General Hospital
- Study coordinator: Maus, Marcela Valderrama
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.